Bonk, Inc 8-K, filed Apr 16, 2021
Bonk, Inc. (BNKK)
About this 8-K
Bonk, Inc filed this 8-K on April 16, 2021.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 16, 2021
JUPITER WELLNESS, INC.
(Exact name of registrant as specified in charter)
| Delaware | 001-39569 | 83-2455880 | ||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
725 N. Hwy A1A, Suite C-106 Jupiter, FL 33477
(Address of principal executive offices) (Zip Code)
(561) 244-7100
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Common Stock | JUPW |
The Nasdaq Stock Market LLC (The Nasdaq Capital Market)
| ||
| Warrants, each exercisable for one share of Common Stock at $8.50 per share | JUPWW |
The Nasdaq Stock Market LLC (The Nasdaq Capital Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company [X]
If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On April 16, 2021, the Board of Directors (the “Board”) of Jupiter Wellness, Inc. (the “Company”) appointed Dr. Glynn Wilson as Chief Science Officer, Rich Miller as Chief Compliance Officer, and Ryan Allison as Chief Operating Officer. Dr. Glynn Wilson, who continues to serve as Chairman of the Board and was formerly Head of Research and Development (R&D), will now serve as Chief Science Officer. Rich Miller continues to serve as a Director and now moves into the key newly created position of Chief Compliance Officer. Ryan Allison, formerly Director Vice President of Business Development, moves into the position of Chief Operating Officer.
Item 7.01 Regulation FD Disclosure
On April 16, 2021, the Company issued the attached press release. A copy of the press release is attached hereto and incorporated herein by reference in its entirety as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
Exhibits
| Exhibit No. | Description | |
| 99.1 | Press release dated April 16, 2021 |
| 1 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 16, 2021
| JUPITER WELLNESS, INC. | ||
| By: | /s/ Brian John | |
| Brian John | ||
| Chief Executive Officer | ||
| 2 |
Exhibit 99.1
Jupiter Wellness to Support Growth in CBD-Based Pharma & Consumer Products
Jupiter, FL – April X, 2021 - Jupiter Wellness, Inc. (Nasdaq: JUPW), a leading developer of cannabidiol (CBD) based medical therapeutics and wellness products, today announced it has appointed Dr. Glynn Wilson as Chief Science Officer, Rich Miller as Chief Compliance Officer, and Ryan Allison as Chief Operating Officer. Over the past quarters, Jupiter has grown its CBD-based consumer wellness business to include 40 products across seven brands in six categories, while also advancing its clinical pipeline with three indications in Phase 1 equivalent studies and one indication ready for an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) based on a successful Phase 1 equivalent which met its primary endpoint.
Dr. Glynn Wilson, who continues to serve as Chairman of the Board and was formerly Head of R&D at Jupiter, will now serve as Chief Science Officer overseeing Jupiter’s pipeline of clinical indications including eczema. Should JW-100 continue to show similar efficacy in advanced stage trials, Jupiter’s lead product candidate would address a $10 billion global market, in which a competing product is projected to reach $2 billion in annual sales. Dr. Wilson will guide the development strategy and clinical design for Jupiter’s CBD-based topical product candidates for indications including skin cancer, burns, and herpes cold sores, all of which are currently in Phase 1 equivalent human trials. Dr. Wilson was formerly Head of Drug Delivery at SmithKline Beecham and was Founder, CEO and Chairman of TapImmune, a developer of cancer vaccines.
Rich Miller continues to serve as a Director for Jupiter and now moves into the newly created position of Chief Compliance Officer overseeing regulatory affairs for securities, CBD-based products, Jupiter’s subsidiaries, manufacturing, and international trade. As Jupiter expands through both organic growth and acquisition, Mr. Miller serves a critical role in assuring the Company defines best practices in innovation as a leader in its industry segments.
Ryan Allison, formerly Vice President of Business Development, moves into the position of Chief Operating Officer overseeing growth as Jupiter capitalizes on unprecedented opportunities in the CBD pharma and wellness space. Mr. Allison is a strong leader who has been at the forefront of building high-performance, data-driven organizations and business infrastructure throughout his career across many industries including healthcare and the federal government. Earlier in his career Mr. Allison served at VMware where he was an early member of the cloud computing team and an instrumental player in securing a foothold in the infant cloud landscape, a market segment VMware continues to lead in today.
“I am confident these new adjustments to our leadership team have Jupiter Wellness prepared for the explosive growth we are expecting to see in the CBD market. I am thrilled that we have access to such high caliber talent across our team as we step into our second quarter.,” stated Brian John, CEO of Jupiter Wellness.
About Jupiter Wellness
Jupiter Wellness, Inc. (NASDAQ: JUPW) is a leading developer of cannabidiol (CBD) based medical
therapeutics and wellness products. The Company’s clinical pipeline of prescription CBD-enhanced skin care therapeutics address
indications including eczema, burns, herpes cold sores, and skin cancer. Jupiter generates revenues from a growing line of proprietary
over-the-counter skincare products including its flagship CaniSun™ sunscreen and other wellness brands sold through its website
www.cbdcaring.com..
For additional information, please visit www.jupiterwellnessinc.com. The Company’s public filings can be found at www.Sec.gov.
Safe
Harbor Statement
To the extent any statements contained in this presentation of Jupiter Wellness, Inc. (the “Company”) contains “forward-looking
statements” as defined in the Private Securities Litigation Reform Act of 1995 and the information that are based upon beliefs of,
and information currently available to, the company’s management as well as estimates and assumptions made by the company’s
management. These statements can be identified by the fact that they do not relate strictly to historic or current facts. When used in
this presentation the words “estimate,” “expect,” intend,” believe,” plan,” “anticipate,”
“projected” and other words or the negative of these terms and similar expressions as they relate to the company or the company’s
management identify forward-looking statements. Such statements reflect the current view of the company with respect to future events
and are subject to risks, uncertainties, assumptions and other factors relating to the company’s industry, its operations and results
of operations and any businesses that may be acquired by the company. Should one or more of these risks or uncertainties materialize,
or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected,
intended, or planned. Although the company believes that the expectations reflected in the forward-looking statements are reasonable,
the company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security
laws of the United States, the company does not intend to update any of the forward-looking statements to conform these statements to
actual results.
Investor & Public Relations Contact Info
Phone: 561-244-7100
Email: info@jupiterwellnessinc.com